Lupin share news and announcements
NSE: LUPINBSE: 500257Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,928.90up ₹6.90 (0.36%)BSE ₹1,925.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,922.00.
52-week range of traded prices to 23 Oct 2026
₹1,892.90Low, 23 Oct 2026₹2,529.50High, 16 Jul 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹88,207 Cr105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 16.0
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 14.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 7 May 2026
- 3.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.93%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 27.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 30.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 28.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 7 May 2026
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,02,15655.7% delivered
Lupin share news and announcements
2,116 announcements, routine notices left out, newest first. Page 42 of 43.
Nov 2007
30 Nov · Allotment of Equity Shares
The Allotment Committee of Directors at its meeting held on November 30, 2007 has allotted 6030 fully paid up equity shares of Rs. 10/- each. These shares have been allotted upon exercising of options granted to the employees under the Stock Option Plans of the Company. In view of the above, the issued and paid up capital of the Company increased to Rs. 820,594,240 consisting 82,059,424 equity shares of Rs. 10/- each.16 Nov · Results
Report, considering Postal Ballot forms received up to the close of working hours on November 15, 2007 was submitted by the Scrutinizer to the Chairman and the result of the Postal Ballot was announced on November 16, 2007. As per the said results, 44,027,842 votes were cast in favour of the Special Resolution and 9,515 votes against it. The Special Resolution was accordingly passed by Special majority.14 Nov · Business
Press release dated November 13, 2007, titled "Lupin gets new Pharmaceutical Research Head". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2007
31 Oct · Allotment of Equity Shares
The Allotment Committee of Directors at its meeting held on October 31, 2007 has allotted 7550 fully paid up equity shares of Rs. 10/- each. These shares have been allotted upon exercising of options granted to the employees under the Stock Option Plans of the Company. In view of the above, the issued and paid up capital of the Company increased to Rs. 820,533,940 consisting 82,053,394 equity shares of Rs. 10/- each.25 Oct · Meeting
Pursuant to the provisions of Section 192A of the Companies Act, 1956 ("Act") read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the following Special Resolution is proposed to be passed by Postal Ballot: Revision w.e.f. July 01, 2007 in the remuneration payable to Mr. Nilesh Gupta, President - Advanced Markets. The Company has appointed Ms. Neena Bhatia, Practising Company Secretary, as the Scrutiniser for conducting the Postal Ballot process in a fair and transparent manner. The duly completed postal ballot form should reach the Scrutiniser on or before the close of working hours on November 15, 2007. The result of the voting by Postal Ballot will be announced on November 16, 2007. A copy of the Notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Oct · Business
Press release dated October 24, 2007, titled "Lupin FY 2007-08 Q2 Consolidated Net Profit up 46% to Rs. 756 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 71432 lacs for quarter ending on 30-SEP-2007 against Rs. 49107 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 11808 lacs for the quarter ending on 30-SEP-2007 against Rs. 5830 lacs for the quarter ending on 30-SEP-2006.24 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 123470 lacs for half year ending on 30-SEP-2007 against Rs. 98022 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 13152 lacs for the half year ending on 30-SEP-2007 against Rs. 10540 lacs for the half year ending on 30-SEP-2006.24 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 65897 lacs for quarter ending on 30-SEP-2007 against Rs. 48391 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 7564 lacs for the quarter ending on 30-SEP-2007 against Rs. 5185 lacs for the quarter ending on 30-SEP-2006.12 Oct · Business
Press release dated October 12, 2007, titled "Lupin sells additional Perindopril patents to Servier". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Oct · Board meeting
Meeting on 24 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”10 Oct · Business
Press release dated October 10, 2007, titled "Lupin acquires in Japan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
28 Sep · Allotment of shares
The Allotment Committee of Directors at its meeting held on September 28, 2007 has allotted 10260 fully paid up equity shares of Rs.10/- each. These shares have been allotted upon exercising the options by the employees under Stock Option Plans of the Company. In view of the above, the issued and paid up capital of the Company increased to Rs.820,458,440 consisting 82,045,844 equity shares of Rs.10/- each27 Sep · Business
Press release dated September 27, 2007, titled "Lupin acquires pharmaceutical business of Rubamin". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Sep · Miscellaneous
The Company is setting up a Unit with an investment of Rs.400 million for the manufacture of Steroids and other formulations at the Special Economic Zone at Indore. The said project would be set-up under Lupin Pharmacare Limited, a wholly owned subsidiary of the Company.13 Sep · Business
Press release dated September 12, 2007, titled "Lupin wins Ramipril product patent challenge at Federal Circuit". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
30 Aug · Allotment of shares
The Allotment Committee of Directors at its meeting held on August 30, 2007 has allotted 22905 fully paid up equity shares of Rs.10/- each. These shares have been allotted upon exercising the options by the employees under Stock Option Plans of the Company. In view of the above, the issued and paid up capital of the Company increased to Rs.820,355,840 consisting 82,035,584 equity shares of Rs.10/- each13 Aug · Business
Press release dated August 13, 2007, titled "Lupin appoints Ramesh Swaminathan as President Finance and Planning". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
31 Jul · Business
Press release dated July 31, 2007, titled "Lupin receives "Best New Manufacturer of the Year" Award from Amerisource Bergen". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Jul · Allotment of shares
The allotment Committee of Directors at its meeting held on July 31, 2007 has allotted 500,693 fully paid up equity shares of Rs.10/- each, the particulars of which are as under:- (1) Issue of shares upon :- exercising the options granted to employees under the stock option plans of the Company; No of shares :- 11205. (2) Issue of shares upon :- conversion of Zero Coupon Foreign Currency convertible Bonds (FCCB) issued by the Company pursuant to the Offering Memorandum dated January 2, 2006; No of shares :- 489488. Total; No of shares :- 500693. In view of the above, the issued and paid up capital of the Company increased to Rs.820,126,790 consisting 82,012,679 equity shares of Rs.10/- each21 Jul · Business
Press release dated July 18, 2007, titled "Lupin receives DCGI Approval to conduct Combined Phase IIb/III Clinical Trials for it's herbal Psoriasis NCE". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jul · Meeting
Following resolutions were passed by the members at the Annual General Meeting of the Company held on July 19, 2007. Ordinary Business :- (1) Dividend @ Rs.5/- per share on 81,511,986 fully paid-up equity shares of Rs.10/- each absorbing a sum of Rs.476,824,740/- (inclusive of tax on dividend of Rs.69,264,810/-) was declared for the year ended March 31, 2007. (2) Dr. Kamal K. Sharma was re-appointed a Director of the Company. (3) Mr. D.K. Contractor was re-appointed a Director of the Company. (4) Mrs. M.D. Gupta was re-appointed a Director of the Company. (5) Deloitte Haskins & Sells, Chartered Accountants, were re-appointed as the statutory auditors to hold office from the conclusion of the Annual General Meeting till the conclusion of the next Annual General Meeting. The Board of Directors was authorised to fix the remuneration payable to M/s. Deloittee Haskins & Sells. Special Business :- (1) Mr. Edward R. Robert was appointed as Director of the Company.19 Jul · Business
Press release dated July 19, 2007, titled "Lupin FY 2007-08 Q1 Net Profit up 55% to Rs.784 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 60175 lacs for quarter ending on 30-JUN-2007 against Rs. 47693 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 7838 lacs for the quarter ending on 30-JUN-2007 against Rs. 5065 lacs for the quarter ending on 30-JUN-2006.19 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 57573 lacs for quarter ending on 30-JUN-2007 against Rs. 50438 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 5588 lacs for the quarter ending on 30-JUN-2007 against Rs. 5355 lacs for the quarter ending on 30-JUN-2006.17 Jul · Business
Press release dated July 17, 2007, titled "Lupin Receives US FDA Approval for Amlodipine". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jul · Board meeting
Meeting on 19 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”2 Jul · Business
Press release dated July 02, 2007, titled "Lupin gets MHRA Approval for Lisinopril in UK". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jul · Allotment of shares
The Allotment Committee of Board at its meeting held on June 29, 2007 has considered and approved allotment of 783,181 equity shares of Rs. 10/- each as under, for cash at a premium in terms of the Offering document, consequent to the conversion of FCCBs amounting to US$ 9.60 million out of US$ 100 million FCCBs issued by the Company in January 2006: 1) Name of the allottee: Morgan Stanley and Co International Limited, No. of shares allotted: 163162; 2) Name of the allottee: Merrill Lynch Capital Markets Espana S.A.S.V, No. of shares allotted: 65265; 3) Name of the allottee: Citigroup global Markets Mauritius Pvt. Ltd., No. of shares allotted: 391591; 4) Name of the allottee: Deutsche Bank AG, London, No. of shares allotted: 163163; Total No. of shares allotted: 783181
Jun 2007
25 Jun · Grant of Options
The Company has granted 36900 options to the employees of its subsidiary company at the exercise price of Rs.692.75 on 20/06/2007. Please note that one equity share of Rs.10/- each is covered by each option. The options issued are exercisable at the 'market price' as defined under SEBI guidelines, in a phased manner after a vesting period of minimum 12 months but before the exercise period of 10 years from the date of grant22 Jun · Meeting
1) The Annual General Meeting of the Company shall be held on July 19, 2007. 2) The Board of Directors at their meeting held on May 09, 2007, have decided to close the Register of Members and Share Transfer Register from July 12, 2007 to July 19, 2007 (both days inclusive) for the purpose of Annual General Meeting and Dividend.19 Jun · Miscellaneous
Lupin Limited and Lupin Pharmaceuticals, Inc. ("Lupin") have reached an end to certain District Court litigation proceedings on Cefdinir. The proceedings emanate from a civil action pending in the United States District Court for the Eastern District of Virginia, captioned Lupin Limited et al. v. Abbott Laboratories and Astellas Pharma, Inc. et al., Civil Action No. 3:06-CV-400. Further the Company has submitted a copy of the Stipulated Order of Dismissal. By this document, Lupin and Abbott Laboratories and Astellas, Inc. have mutually dismissed various claims against each other without prejudice. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jun · Business
Press release dated June 14, 2007, titled "Lupin receives Final FDA Approval for Trandolapril". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
31 May · Business
Two press releases dated May 31, 2007, titled "Lupin and Symbiotee decide not to pursue their MoU" and "Lupin receives US FDA approval for Cefadroxil Capsules." The details of the press releases shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 May · Allotment of shares
The Allotment Committee of Board at its meeting held on May 30, 2007 has considered and approved allotment of 138,687 equity shares of Rs. 10/- each as under, for cash at a premium in terms of the Offering document, consequent to the conversion of FCCBs amounting to US$ 1.7 million out of US$ 100 million FCCBs issued by the Company in January, 2006: 1) Name of the allottee - Merrill Lynch Capital Markets Espana S.A.S.V; No. of shares allotted - 40790; 2) Name of the allotee - Merrill Lynch Capital Markets Espana S.A.S.V; No. of shares allotted - 40790; 3) Name of the allotee - Morgan Stanley and Co International Limited; No. of shares allotted - 57107; Total - 13868730 May · Allotment of shares
The Allotment Committee of Board at its meeting held on May 30, 2007 has allotted 810 equity shares of Rs.10/- each to the employee of the Company, upon exercising the options granted under Lupin Employees Stock Option Plan 200321 May · Grant of Options
The Company has granted 37260 options to its employees at the exercise price of Rs.706.85 on 15/05/2007. Please note that one equity share of Rs.10/- each is covered by each option. The options issued are exercisable at the 'market price' as defined in SEBI guidelines, in a phased manner after a vesting period of minimum 12 months but before the exercise period of 10 years from the date of grant21 May · Allotment
Allotment Committee of Board at its meeting held on May 14, 2007 has considered and approved allotment of 244,744 equity shares of Rs. 10/- each, for cash at a premium in terms of the Offering document, to 'Goldman Sachs Investments (Mauritius) I Ltd.' consequent upon conversion of FCCBs amounting to US$3,000,000, out of US$ 100,000,000 FCCBs issued by the Company in January, 2006.21 May · Business
Press release dated May 21, 2007, titled "Lupin receives tentative US FDA Approval for Ziprasidone". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 May · Business
Press release dated May 15, 2007, titled "Lupin receives US FDA approval for Simvastatin Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 May · Business
Press release dated May 09, 2007, titled "Lupin and Symbiotec join hands on Steroids". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 May · Formation of a subsidiary
Board of Directors of the Company, in their meeting held on May 09, 2007, approved the formation of a wholly owned subsidiary in Switzerland by making an initial investment of up to Swiss Francs 100,000 (US $ 83,000). The said subsidiary would act as a special purpose vehicle for routing overseas investments to be made by the Company. The Board further approved the formation of a subsidiary in India with an initial investment of Rs.500,000/-. The said subsidiary would undertake manufacture of Active Pharmaceutical Ingredients at a unit to be located in a Special Economic Zone.9 May · Business
Press release dated May 09, 2007, titled "Lupin FY 2006-07 Net Profit up 65% to Rs.3021 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 May · Dividend
At the meeting of the Board of Directors held on May 09, 2007, the Board recommended for the year ended March 31, 2007, dividend @ 50% i.e. Rs.5/- per equity share of the face value of Rs.10/- each.9 May · Business
Press release dated May 08, 2007, titled "Lupin receives FDA Approval of Cefdinir for Oral Suspension, 250 mg/5mL, launches complete range in the US". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
27 Apr · Business
Collaboration between the Department of Science and Technology, Government of India and Lupin Limited for clinical development of the Company's Migraine and Psoriasis projects. Further the Company has submitted to the Exchange a copy of the press release dated April 27, 2007, titled "DST and Lupin join hands over Migraine Psoriasis". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Apr · Board meeting
Inter alia, to consider the audited accounts for the year ended March 31, 2007 and recommend dividend, if any.12 Apr · Business
Press release dated April 12, 2007, titled "Lupin receives US FDA Approval for Novel Formulation of Suprax (R) Suspension". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Apr · Results
The last accounting year of the Company ended on March 31, 2007 and we intend to finalise and publish the audited results for the said year within the time stipulated by clause 41 of the Listing Agreement. In view of the above, publication of the unaudited results for the last quarter i.e. January 01, 2007 to March 31, 2007 is not necessary.5 Apr · Business
Press release, dated April 5, 2007, titled "Lupin finalizes patent sale agreement with Servier". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.